Pharmacogenomics and reducing the frequency of adverse drug events

Author： O’Kane Dennis J   Weinshilboum Richard M   Moyer Thomas P  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.4, Iss.1, 2003-01, pp. : 1-4

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Pharmacogenetics and pharmacogenomics: adverse drug reactions

By Jorgensen Andrea   Alfirevic Ana  

Pharmacogenomics, Vol. 9, Iss. 10, 2008-10 ,pp. : 1397-1401

Future Medicine

Access to resources Recommend Favorite

Adverse drug events in outpatients

By  

Inpharma, Vol. 1, Iss. 1385, 2003-01 ,pp. : 29-29

Adis International

Access to resources Recommend Favorite

Pharmacogenomics and adverse drug reactions: the case of statins

By Giorgi Mariano A   Caroli Christian   Arazi Hernáán Cohen   Di Girolamo Guillermo  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 10, 2011-07 ,pp. : 1499-1509

Informa Healthcare

Access to resources Recommend Favorite

Pharmacogenomics of adverse drug reactions: practical applications and perspectives

By Becquemont Laurent  

Pharmacogenomics, Vol. 10, Iss. 6, 2009-06 ,pp. : 961-969

Future Medicine

Access to resources Recommend Favorite

Defining targets for investigating the pharmacogenomics of adverse drug reactions to antifungal agents

By Meletiadis Joseph   Chanock Stephen   Walsh Thomas J  

Pharmacogenomics, Vol. 9, Iss. 5, 2008-05 ,pp. : 561-584

Future Medicine

Access to resources Recommend Favorite